{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:56Z","timestamp":1760146076000,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives: To compare the clinical outcomes of intravenous carboplatin\/paclitaxel chemotherapy plus bevacizumab versus intraperitoneal cisplatin\/paclitaxel chemotherapy without bevacizumab as the frontline treatment in women with advanced ovarian, fallopian tube and primary peritoneal cancer. Methods: Between November 2012 and January 2024, medical records of all consecutive women with stage II~IV cancer treated with either frontline adjuvant intraperitoneal cisplatin\/paclitaxel without bevacizumab (IP group), intravenous carboplatin\/paclitaxel without bevacizumab (IV group) or intravenous carboplatin\/paclitaxel with bevacizumab (IVB group) at a tertiary referral center were reviewed. Results: A total of 143 women (IP group, n = 57; IVB group, n = 23; IV group, n = 63) were reviewed. The IP group had greater progression-free survival compared to the IVB group (49.1 months, 95% confidence interval [CI] = 27.8 months to infinity, versus 11.9 months, 95% CI = 11.2 to 16.2 months; adjusted hazard ratio [HR] = 0.45, 95% CI = 0.24 to 0.87, p = 0.017). Additionally, the IP group also had a higher overall survival compared to the IVB group (not reached, 95% CI = 55.6 months to infinity, versus 38.9 months, 95% CI = 21.9 months to infinity; adjusted HR = 0.34, 95% CI = 0.15 to 0.79, p = 0.012). Conclusions: Intraperitoneal cisplatin\/paclitaxel chemotherapy without bevacizumab seems to offer a survival advantage when compared with intravenous carboplatin\/paclitaxel with bevacizumab in the frontline treatment of women with advanced ovarian cancer.<\/jats:p>","DOI":"10.3390\/cancers16193382","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:45:52Z","timestamp":1727937952000},"page":"3382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer"],"prefix":"10.3390","volume":"16","author":[{"given":"Wan-Hua","family":"Ting","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220216, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan 320315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220216, Taiwan"},{"name":"Graduate Institute of Medicine, Yuan Ze University, Taoyuan 320315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chow","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220216, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsu-Dong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220216, Taiwan"},{"name":"Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-9564","authenticated-orcid":false,"given":"Sheng-Mou","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220216, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei 100226, Taiwan"},{"name":"Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan 320315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"ref_1","unstructured":"(2024, July 23). National Comprehensive Cancer Network Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 3.2024). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stegel, V., Blatnik, A., \u0160kof, E., Drago\u0161, V.\u0160., Krajc, M., Gregori\u010d, B., \u0160kerl, P., Strojnik, K., Klan\u010dar, G., and Banjac, M. (2022). Real-World Data on Detection of Germline and Somatic Pathogenic\/Likely Pathogenic Variants in BRCA1\/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing. Cancers, 14.","DOI":"10.3390\/cancers14061434"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology\/Gynecologic Oncology Group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","article-title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for ad-vanced ovarian cancer?","volume":"28","author":"Monk","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: Prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ting, W.H., Hsiao, C.H., Chen, H.H., Wei, M.C., Lin, H.H., and Hsiao, S.M. (2020). Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum\/Paclitaxel Chemotherapy without Bevacizumab. Int. J. Environ. Res. Public. Health, 17.","DOI":"10.3390\/ijerph17103603"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2019.02.004","article-title":"Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of M\u00fcllerian origin","volume":"153","author":"Krasner","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"EVIDoa2200225","DOI":"10.1056\/EVIDoa2200225","article-title":"Intraperitoneal Carboplatin for Ovarian Cancer\u2014A Phase 2\/3 Trial","volume":"2","author":"Nagao","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure","volume":"89","author":"Derick","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2010.32.2701","article-title":"Lessons from the adjuvant bevacizumab trial on colon cancer: What next?","volume":"29","author":"Lambrechts","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2009.05.034","article-title":"Importance of delivered cycles and nomo-gram for intraperitoneal chemotherapy in ovarian cancer","volume":"114","author":"Yen","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3802\/jgo.2019.30.e11","article-title":"Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: What is the best age cutoff?","volume":"30","author":"Kim","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/sj.bjc.6603457","article-title":"Ovarian cancer in younger vs older women: A population-based analysis","volume":"95","author":"Chan","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13048-020-0614-1","article-title":"Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: A preliminary model study","volume":"13","author":"Feng","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000076236","article-title":"Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level","volume":"57","author":"Obeidat","year":"2004","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2008.10.010","article-title":"A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma","volume":"112","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/cncr.24084","article-title":"The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: A Gynecologic Oncology Group study","volume":"115","author":"Zorn","year":"2009","journal-title":"Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:46Z","timestamp":1760112586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cancers16193382"],"URL":"https:\/\/doi.org\/10.3390\/cancers16193382","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}